Ton Lisman

Platelet function in patients with cirrhosis.

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Haemostatic abnormalities in patients with liver disease.

Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.

Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis.

Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor.

Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation.

Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.

Circulating endothelial cells in cancer patients do not express tissue factor.

Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis.

Platelet aggregation: involvement of thrombin and fibrin(ogen).

Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy.

Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow.

Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.

Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts.

Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1.

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients.

A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides.

Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related?

Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

Fibrinolysis and the risk of venous and arterial thrombosis.

Role of fibrin sealants in liver surgery.

Antiplatelet medication after liver transplantation: does it affect outcome?

Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment.

Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A.

The influence of the pulsatility of the blood flow on the extent of platelet adhesion.

A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans.

Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.

Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions.

Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis.

Interlaboratory variability in assessment of the model of end-stage liver disease score.

Tissue factor-independent effects of recombinant factor VIIa on hemostasis.

Platelets in liver transplantation: friend or foe?

The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface.

Salvianolic acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor alpha2beta1.

The two tales of coagulation in liver transplantation.

Hepatic artery thrombosis after liver transplantation: more than just a surgical complication?

The platelet and platelet function testing in liver disease.

Bleeding in liver surgery: prevention and treatment.

Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men.

Hypofibrinolysis is a risk factor for arterial thrombosis at young age.

Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia.

Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury.

Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.

Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point-of-care testing with the thromboelastography analyser.

Inflammation mediated down-regulation of hepatobiliary transporters contributes to intrahepatic cholestasis and liver damage in murine biliary atresia.

No evidence for systemic platelet activation during or after orthotopic liver transplantation.

Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation.

The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.

Factor XI binding to platelets: glycoprotein Ib alpha has an accomplice.

Immediate postoperative low platelet count is associated with delayed liver function recovery after partial liver resection.

How to minimize blood loss during liver surgery in patients with cirrhosis.

Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy?

Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests.

The interaction of recombinant factor VIIa with platelet glycoprotein Ib.

Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome.

Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences.

Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.

The role of platelets in liver inflammation and regeneration.

Hemostasis and thrombosis in patients with liver disease: the ups and downs.

Activation and regulation of hemostasis in acute liver failure and acute pancreatitis.

The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver.

The combination of primary sclerosing cholangitis and CCR5-Δ32 in recipients is strongly associated with the development of nonanastomotic biliary strictures after liver transplantation.

Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction.

Protection of bile ducts in liver transplantation: looking beyond ischemia.

Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography.

Towards a rational use of low-molecular-weight heparin in patients with cirrhosis.

Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation.

Recombinant factor VIIa to treat severe bleeding in patients with liver disease: pitfalls and possibilities.

Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study.

Regeneration of human extrahepatic biliary epithelium: the peribiliary glands as progenitor cell compartment.

Pitfalls in assessing platelet activation status in patients with liver disease.

Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood.

Platelet function in stored heparinised autologous blood is not superior to in patient platelet function during routine cardiopulmonary bypass.

Prohemostatic interventions in liver surgery.

Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury.

Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants.

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

The impact of hepatic steatosis on liver regeneration after partial hepatectomy.

An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.

Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient.

Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.

Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding.

Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial.

Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels.

Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.

Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy.

Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.

Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death.

Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures.

Hemostasis in liver disease: implications of new concepts for perioperative management.

Management of coagulation abnormalities in liver disease.

Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions.

Early elevated serum gamma glutamyl transpeptidase after liver transplantation is associated with better survival.

Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis.

Low molecular weight heparin in management and prevention of portal vein thrombosis.

Issues with monitoring of unfractionated heparin in cirrhosis.

Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma.

Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation.

Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion.

No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma.

Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?

Coagulation activation during air travel is not initiated via the extrinsic pathway.

Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.

Evidence against a role of serotonin in liver regeneration in humans.

The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa.

Letter by Hugenholtz and Lisman regarding article, "plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".

Development of a hypercoagulable status in patients undergoing off-pump lung transplantation despite prolonged conventional coagulation tests.

Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis.